A Study to Evaluate Tocilizumab Treatment in a Real-Life Setting

CRP and BMI Study: Evaluation in Real Life of Clinical Remission Rate and Correlation Between CRP and BMI in Patients Treated With Tocilizumab

This observational, multi-center study will evaluate the treatment regimen, treatment responses and safety of tocilizumab therapy in a routine clinical practice in participants with moderate to severe rheumatoid arthritis (RA). Data will be collected for 6 months with a maximum study duration of 18 months.

Inclusion Criteria:

• Diagnosis of moderate to severe RA according to revised American College of Rheumatology criteria
• Participants have started tocilizumab treatment according to routine clinical practice within 3 months prior to site opening and still in treatment, as well as participants who began treatment at enrollment

Exclusion Criteria:

• Participants who have started tocilizumab treatment more than 3 months prior to site opening
• Participants who have previously received tocilizumab in a clinical trial setting or for compassionate use
• Participants who have been enrolled in an ongoing clinical trial and/or have received treatment with any investigational drug within 4 weeks prior to study start
• Participants with a history of autoimmune disease or joint inflammatory disease other than RA